-
CDK 関連製品 (477)
関連製品 (477)
-
CDK9-Cyclin T1 PPI-IN-1
0 Images製品番号: HY-156296CAS 番号: 2995336-58-6CDK9-Cyclin T1 PPI-IN-1 (Compound B19) is a selective CDK9-Cyclin T1 protein-protein interaction (PPI) inhibitor. CDK9-Cyclin T1 PPI-IN-1 inhibits cell proliferation in TNBC MDA-MB-231 cells (IC50: 0.044 μM), and induces apoptosis. CDK9-Cyclin T1 PPI-IN-1 inhibits CDK9 transcription activity, reduces the phosphorylation of RNA Pol II CTD ser2. CDK9-Cyclin T1 PPI-IN-1 inhibits tumor growth in a TNBC 4T1 mouse model.
-
KM05382
0 Images製品番号: HY-123668CAS 番号: 882291-64-7KM05382 serves as an inhibitor of CDK9 and reduces the transcription of GAPDH.
-
ODN BW001
0 Images製品番号: HY-150213CAS 番号: 886862-38-0ODN BW001 is an oligodeoxynucleotide (ODN). ODN BW001 plays a regulatory role in the proliferation and activation of osteoblast.
-
p27
0 Images製品番号: HY-P11013CAS 番号: 959369-94-9
-
CDK12/CycK Recombinant Human Active Protein Kinase
0 Images製品番号: HY-E70659CDK12/CycK Recombinant Human Active Protein Kinase is a cyclin-dependent kinase that phosphorylates the C-terminal domain (CTD) of RNA polymerase II (Pol II), thereby regulating different phases of the transcription cycle from transcription initiation to elongation and termination.
-
KGA-4066
0 Images製品番号: HY-180222KGA-4066 is a novel non-ATP-competitive CDK2 inhibitor. KGA-4066 inhibits CDK2/Cyclin A2 with an IC50 value of 236.7 nM, disrupts their interaction, promots CDK2 degradation via the lysosomal pathway. KGA-4066 has anticancer activity against hepatocellular carcinoma.
-
Roccellic acid
0 Images製品番号: HY-N12218CAS 番号: 29838-46-8別名: (+)-Roccellic acid; NSC 249985Roccellic acid is a methanol extract of Roccella montagnei with cytotoxicity with an IC50 value of 71.26 μg/ml.
-
CDK1/CycB1 Recombinant Human Active Protein Kinase
0 Images製品番号: HY-E70653CDK1 is a cyclin-dependent kinase that functions as a serine/threonine protein kinase, and is a key player in cell cycle regulation. CDK1/CycB1 Recombinant Human Active Protein Kinase is an ortholog of CDK1. CDK1/cyclin B1 complexes initiates mitotic entry by phosphorylating a multitude of proteins to condense chromosomes, disrupt the nuclear envelope, and enable microtubules polymerization to attach and to segregate the chromosomes.
-
CDK4/6-IN-17
0 Images製品番号: HY-153704CAS 番号: 2035069-96-4CDK4/6-IN-17 (compound 12) is an orally active CDK4/6 inhibitor with IC50 ranging of 10-100 nM in BE(2) cells. CDK4/6-IN-17 inhibits tumor growth in COLO205 xenograft model.
-
(rac)-ZK-304709
0 Images製品番号: HY-19471CAS 番号: 1010440-84-2(rac)-ZK-304709 is an isoform of ZK-304709 and is an orally active multi-targeted tumor growth inhibitor that inhibits multiple cell cycle-dependent kinases (CDKs), vascular endothelial growth factor receptor kinases (VEGF-RTKs), and platelet-derived growth factor receptor kinase β (PDGF-RTKβ). (rac)-ZK-304709 can dose-dependently inhibit the proliferation and colony formation of neuroendocrine tumor (NET) cells. (rac)-ZK-304709 directly acts on NET cells by inducing G2 cell cycle arrest and apoptosis, while reducing the expression of MCL1, survivin, and HIF1α. (rac)-ZK-304709 effectively controls tumor growth by inducing apoptosis and inhibiting tumor-induced angiogenesis, and may become a potential agent for inhibiting NET.
-
CDK2-IN-49
0 Images製品番号: HY-179161CDK2-IN-49 (Compound 5j) is a CDK2 inhibitor with an IC50 of 0.25 μM. CDK2-IN-49 shows potent activity against CDK7 with an IC50 of 0.14 μM. CDK2-IN-49 induces Apoptosis by raising the levels of p53 and Bax protein expression while reducing the amount of Bcl-2. CDK2-IN-49 inhibits cell division. CDK2-IN-49 can be used in the research of cancer.
-
CDK2/CycA2 Recombinant Human Active Protein Kinase
0 Images製品番号: HY-E70670CDK2 is a cyclin-dependent kinase involved in the control of the cell cycle. CDK2/CycA2 Recombinant Human Active Protein Kinase is an ortholog of CDK2.
-
EGFR/CDK2-IN-4
0 Images製品番号: HY-156116EGFR/CDK2-IN-4 (compound 4c) is a dual inhibitor of EGFR and CDK-2 with IC50s of 89.6 and 165.4 nM, respectively. EGFR/CDK2-IN-4 induces apoptosis in MCF-7 cells and arrests the cell cycle in the S phase. EGFR/CDK2-IN-4 has significant anti-cancer cell toxicity and inhibits MCF-7 with an IC50 of 2.74 μM.
